Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.
At the ongoing AACR Immuno-Oncology Conference (AACR IO) in Los Angeles, Ampersand Biomedicines Inc. gave a presentation on promising results in the field regarding AMP-410, an anti-VEGF/4-1BB antibody construct that limits 4-1BB activation in VEGF-rich tumor types, thus achieving durable efficacy.
Lario Therapeutics Ltd. has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform. The funding provides validation of Lario’s work on selective small-molecule inhibitors of voltage-gated neuronal calcium channels.
Animate Biosciences Inc.’s lead therapeutic peptide MBb32 produced a significant reduction in cardiac scar tissue and subsequent recovery of heart function in a mouse model of severe myocardial injury.
On the average, humans – and pigs, and deer, and birds – who live at high altitudes have better blood glucose control than their counterparts near sea level. In work published in the Feb. 19, 2026, issue of Cell Metabolism, investigators have linked this phenomenon to red blood cells that directly take up and metabolize glucose from the blood under low oxygen conditions.
Shanghai SIMR Biotech Co. Ltd. has prepared and tested new GABA-A receptor subunit α5 (GABRA5) inverse agonists. They are reported to be useful for the treatment of pain, stroke and Alzheimer’s disease.
Tarapeutics Science Inc. has reported new pyrazolopyridine compounds acting as dual specificity protein kinase CLK and dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) inhibitors.
East China Normal University and Fudan University have jointly discovered tricyclic pyrimidine compounds acting as adenosine A2A and/or A2B receptor antagonists.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
RSS
